Basic Information
| LncRNA/CircRNA Name | lncRNA-HEIH |
| Synonyms | HEIH, HCCAT2, LINC-HEIH, LINC00848, lncRNA-HEIH |
| Region | GRCh38_5:180829954-180831605 |
| Ensemble | ENSG00000278970 |
| Refseq | NR_045680 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | PTX | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Endometrial Cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | Human endometrial cancer cell lines (Ishikawa, HHUA) and hESC (Human endometrial stromal cells), endometrial tumor tissues and their adjacent tissues |
| Expression Pattern | up-regulated |
| Function Description | LncRNA HEIH, the dysregulation of which involved in production of drug-resistance, was overexpressed in PTX-resistant endometrial cancer cells. Up-regulating HEIH would activate MAPK pathway, promote chemo-resistance of endometrial cancer cells and enhance cell proliferation and viability, whereas silencing HEIH depressed the MAPK signaling pathway, contributed to restoring chemo-sensitivity to PTX and repressed cell physiological process. Down-regulating lncRNA HEIH expression reversed the PTX-resistance of endometrial cancer cells through MAPK signaling pathway. Keywords Endometrial cancer . H |
| Pubmed ID | 31650338 |
| Year | 2019 |
| Title | LncRNA HEIH Enhances Paclitaxel-Tolerance of Endometrial Cancer Cells via Activation of MAPK Signaling Pathway |
External Links
| Links for lncRNA-HEIH | GenBank HGNC NONCODE |
| Links for Endometrial Cancer | OMIM COSMIC |